In brief
- Resilient Pharmaceuticals, the company formerly known as Lykos Therapeutics, has resubmitted its application to the FDA for approval of MDMA-assisted therapy for post-traumatic stress disorder.
- The company is proceeding without repeating the Phase 3 trial suggested by the agency in 2024, instead providing a cardiac safety study with 32 volunteers, follow-up data from a Department of Veterans Affairs study, and an audit of the original data.
- The move comes shortly after the FDA published its final guidance in July on how clinical research with psychedelics should be designed.
Two years after the FDA rejected MDMA-assisted therapy for post-traumatic stress disorder, the application is back on the table. Resilient Pharmaceuticals, the successor to Lykos Therapeutics and the commercial arm of the MAPS organization, confirmed in early August that it has resubmitted its authorization request with a different dossier than the one the agency turned down in 2024.
What the FDA requested and what has changed
The letter the agency issued on August 9, 2024, was not a flat refusal, but rather a “not yet.” It highlighted three areas of concern: the Phase 3 trial had not systematically captured the positive effects described by some participants, data on the duration of the benefit was lacking, and a significant portion of the volunteers had used MDMA prior to the study, which complicated the maintenance of blinding. Instead of repeating the Phase 3 trial from scratch, Resilient has chosen to bolster the file with new components: a Phase 1 study in 32 healthy volunteers with cardiac and QT interval monitoring, long-term follow-up data from a study conducted with the U.S. Department of Veterans Affairs, and an independent audit reviewing protocol deviations detected in the original trials.
A new guide and a different context
The resubmission arrives just after the FDA published, on July 14, the final version of its guidance Psychedelic Drugs: Considerations for Clinical Investigations, the first document to set out in writing how the agency expects trials with these substances to be designed: how to mitigate functional unblinding, what abuse risk assessments are required, and what surveillance will be requested following potential approval. Rick Doblin, founder of MAPS, summarized the sentiment of this second attempt by stating that they knew the FDA was not saying no, but rather “not yet.” The company is considering the brand name Rysanso if the molecule is approved.
What it implies
Repeating an application without a new trial is a gamble. Resilient is confident that a reinforced dossier will be enough to convince the agency without having to recruit patients for years, but the history of the file, including an advisory panel that voted against it in 2024, makes it clear that the path is not yet clear. The FDA may request further information. For those who follow the field of psychedelics as a therapeutic pathway, the case illustrates the friction between regulatory requirements and the actual practice of substance-assisted support, an area where harm reduction has spent years documenting safety protocols regardless of whether an approved drug exists.
Source
- MAPS. MAPS Responds to Report of Progress for MDMA-assisted Therapy for PTSD with FDA. maps.org, August 10, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
